How AZ and Amgen’s Tezspire respiratory data ups the ‘level of ambition’ in immunology
After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma ...
AstraZeneca to invest $2.5 billion in Beijing hub as it looks beyond Chinese tax probe
British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development ...
AstraZeneca’s (AZN) “Buy” Rating Reiterated at Berenberg Bank
Berenberg Bank reaffirmed their buy rating on shares of AstraZeneca (LON:AZN – Free Report) in a research report sent to ...
Fierce Biotech10d
AstraZeneca details $2.5B investment in China's political center, funding R&D center, biotech pacts
Tallying up a wide range of investments, AstraZeneca said it is pumping $2.5 billion into Beijing. The figure includes ...
AstraZeneca investing $2.5 billion in China as drugmaker seeks to recover from scandals
AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker ...
Yahoo Finance4d
How AZ and Amgen’s Tezspire respiratory data ups the ‘level of ambition’ in immunology
Andrew Menzies-Gow Vice president, respiratory and immunology, AstraZeneca By reducing cytokine release in the airway’s first line of defense, the epithelium, Tezspire is potentially more ...
NBC New York10d
AstraZeneca to invest $2.5 billion in Beijing hub as it looks beyond Chinese tax probe
and market vaccines for respiratory and other infectious diseases. The partnership with BioKangtai will see the company open its first vaccine manufacturing facility in China. AstraZeneca's ...